Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells

Fig. 6

PDPK1 is activated in LRCC and silencing augments response to gemcitabine. a Immunoblots of LRCC and NLRCC fractions from MiaPaCa2, Panc-1, and Nor-P1 cells probed with anti-phospho PDPK1, anti-phospho AKT. Equal amounts of protein loaded, anti-AKT and β-Actin control on bottom. b Immunofluoresence of LRCC and NLRCC populations from MiaPaCa2, Panc-1, and Nor-P1 cells measuring anti-phosphatidylinositol 3,4,5-trisphosphate levels. Normalized mean of staining intensity for each population shown on the right. c Viability of pancreas cancer cells treated with gemcitabine alone (blue) or in combination with the PDPK1 inhibitor BX795 (purple) or AR-12 (red). d Induction of apoptosis in pancreas cancer cells treated with gemcitabine alone or in combination with the PDPK1 inhibitors BX795 and AR-12

Back to article page